
ACHV Stock Forecast & Price Target
ACHV Analyst Ratings
Bulls say
Achieve Life Sciences Inc. is positioned favorably within the pharmaceutical market due to its commitment to advancing cytisinicline, an established treatment for nicotine addiction that has demonstrated significant efficacy and a favorable safety profile. The company reported impressive market data, with smoking cessation rates showing a dose-dependent improvement, suggesting strong potential for achieving higher sales, which reached $1.6 billion. Furthermore, the planned expansion into the vaping segment and the availability of flexible dosing schedules enhance the product's appeal, potentially driving long-term appreciation in shareholder value.
Bears say
Achieve Life Sciences faces a negative outlook primarily due to concerns regarding the commercial viability of cytisinicline, despite its statistical efficacy in reducing nicotine addiction symptoms. Analyst projections illustrate a bear case scenario where, although cytisinicline may gain approval for cigarette smoking cessation, it is expected to underperform in sales due to slower than anticipated market adoption and decreased penetration in the vaping segment. Furthermore, the observed clinical challenges, such as reliance on alternative therapies like bupropion among depressed patients, may further hinder cytisinicline's market success and overall revenue potential.
This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
ACHV Analyst Forecast & Price Prediction
Start investing in ACHV
Order type
Buy in
Order amount
Est. shares
0 shares